Eisai cuts sales outlook as Aricept begins to lose ground
This article was originally published in Scrip
Executive Summary
Eisai has cut its sales forecast for the fiscal year ending 31 March following the first signs of weakness for mainstay product Aricept (donepezil) for Alzheimer's disease.